[go: up one dir, main page]

MX2018005987A - Compuestos heterociclicos para el tratamiento de enfermedades. - Google Patents

Compuestos heterociclicos para el tratamiento de enfermedades.

Info

Publication number
MX2018005987A
MX2018005987A MX2018005987A MX2018005987A MX2018005987A MX 2018005987 A MX2018005987 A MX 2018005987A MX 2018005987 A MX2018005987 A MX 2018005987A MX 2018005987 A MX2018005987 A MX 2018005987A MX 2018005987 A MX2018005987 A MX 2018005987A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
compounds
heterociclical
heterociclical compounds
Prior art date
Application number
MX2018005987A
Other languages
English (en)
Other versions
MX382092B (es
Inventor
Harris Jason
Mohan Raju
Nuss John
Original Assignee
Oppilan Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oppilan Pharma Ltd filed Critical Oppilan Pharma Ltd
Publication of MX2018005987A publication Critical patent/MX2018005987A/es
Publication of MX382092B publication Critical patent/MX382092B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen compuestos heterocíclicos, composiciones y métodos para su uso para el tratamiento de enfermedades.
MX2018005987A 2015-11-13 2016-11-11 Compuestos heterocíclicos para el tratamiento de enfermedades. MX382092B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
MX2018005987A true MX2018005987A (es) 2018-11-29
MX382092B MX382092B (es) 2025-03-04

Family

ID=58696139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005987A MX382092B (es) 2015-11-13 2016-11-11 Compuestos heterocíclicos para el tratamiento de enfermedades.

Country Status (22)

Country Link
US (4) US10683291B2 (es)
EP (2) EP3373931B1 (es)
JP (3) JP6933384B2 (es)
KR (1) KR102720397B1 (es)
CN (2) CN114149424B (es)
AU (2) AU2016353348A1 (es)
BR (1) BR112018009745B1 (es)
CA (1) CA3005236C (es)
DK (1) DK3373931T3 (es)
ES (1) ES2932049T3 (es)
HR (1) HRP20221417T1 (es)
HU (1) HUE060594T2 (es)
IL (1) IL259297B2 (es)
LT (1) LT3373931T (es)
MX (1) MX382092B (es)
PL (1) PL3373931T3 (es)
PT (1) PT3373931T (es)
RS (1) RS63837B1 (es)
RU (1) RU2727194C2 (es)
SI (1) SI3373931T1 (es)
SM (1) SMT202300062T1 (es)
WO (1) WO2017083756A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3373931T3 (pl) 2015-11-13 2023-02-06 Oppilan Pharma Ltd. Związki heterocykliczne do leczenia choroby
US20210163485A1 (en) * 2017-05-17 2021-06-03 Oppilan Pharma Ltd. Heterocyclic Compounds for the Treatment of Disease
US20200071327A1 (en) * 2017-05-17 2020-03-05 Oppilan Pharma Ltd. Prodrugs for the Treatment of Disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
CN119836422A (zh) 2022-07-06 2025-04-15 奥比兰制药有限公司 S1p受体调节剂的结晶形式
EP4649080A1 (en) * 2023-01-13 2025-11-19 Oppilan Pharma Ltd. Preparation of an s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
CA2672616A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
WO2010065760A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
WO2010117662A1 (en) 2009-03-30 2010-10-14 Exelixis, Inc. Modulators of s1p and methods of making and using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
PH12012500938A1 (en) 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
US8822510B2 (en) * 2010-07-20 2014-09-02 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-Oxadiazole compounds
KR20140077965A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
PL3373931T3 (pl) 2015-11-13 2023-02-06 Oppilan Pharma Ltd. Związki heterocykliczne do leczenia choroby

Also Published As

Publication number Publication date
IL259297B (en) 2022-11-01
AU2021202945B2 (en) 2022-06-23
EP3373931A4 (en) 2019-04-03
BR112018009745A8 (pt) 2019-02-26
CA3005236A1 (en) 2017-05-18
JP6933384B2 (ja) 2021-09-08
MX382092B (es) 2025-03-04
US20190241556A1 (en) 2019-08-08
JP7174963B2 (ja) 2022-11-18
CN114149424A (zh) 2022-03-08
CA3005236C (en) 2024-02-20
JP7445325B2 (ja) 2024-03-07
CN114149424B (zh) 2025-05-13
BR112018009745B1 (pt) 2023-09-26
DK3373931T3 (da) 2022-11-28
US20200325135A1 (en) 2020-10-15
WO2017083756A1 (en) 2017-05-18
JP2018535261A (ja) 2018-11-29
PT3373931T (pt) 2022-12-06
LT3373931T (lt) 2023-03-10
US20230339944A1 (en) 2023-10-26
AU2016353348A1 (en) 2018-07-05
HRP20221417T1 (hr) 2023-02-03
RU2018121416A (ru) 2019-12-13
HUE060594T2 (hu) 2023-03-28
US20220227767A1 (en) 2022-07-21
KR102720397B1 (ko) 2024-10-21
US10683291B2 (en) 2020-06-16
AU2021202945A1 (en) 2021-06-03
IL259297B2 (en) 2023-03-01
JP2021191753A (ja) 2021-12-16
RS63837B1 (sr) 2023-01-31
RU2018121416A3 (es) 2019-12-17
RU2727194C2 (ru) 2020-07-21
PL3373931T3 (pl) 2023-02-06
BR112018009745A2 (pt) 2018-11-06
JP2023017862A (ja) 2023-02-07
CN108463222B (zh) 2021-10-22
EP3373931A1 (en) 2018-09-19
SI3373931T1 (sl) 2023-02-28
ES2932049T3 (es) 2023-01-09
IL259297A (en) 2018-07-31
EP3373931B1 (en) 2022-09-28
SMT202300062T1 (it) 2023-03-17
EP4163281A1 (en) 2023-04-12
CN108463222A (zh) 2018-08-28
KR20180095811A (ko) 2018-08-28

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2017003404A1 (es) Compuestos antibacterianos
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX378273B (es) Compuestos activos hacia bromodominios.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2015002897A1 (es) Inhibidores de bace1
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения